

October 4, 2021

British Columbia Securities Commission

Dear Sirs / Mesdames:

Re: HAVN Life Sciences Inc.

We refer to the short form base shelf prospectus of HAVN Life Sciences Inc. (the "Company") dated October 4, 2021 relating to the offering for sale of common shares, debt securities, subscription receipts, warrants and units, or any combination of such securities (collectively, the "Securities") with a total offering price of the Securities, in the aggregate, of up to \$25,000,000.

We consent to being named and to the use, through incorporation by reference in the above-mentioned short form base shelf prospectus, of our report dated August 30, 2021 to the shareholders of the Company on the following financial statements:

- Consolidated statements of financial position as at April 30, 2021 and 2020;
- Consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for the year ended April 30, 2021 and the period from incorporation on April 8, 2020 to April 30, 2020, and a summary of significant accounting policies and other explanatory information.

We report that we have read the short form base shelf prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the short form base shelf prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



CHARTERED PROFESSIONAL ACCOUNTANTS